Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olokizumab and Goflikicept (RPH-104) in Severe COVID-19
NCT04380519Phase 3Completed
- Sponsor
- R-Pharm
- Start
- Apr 2020
- Primary completion
- Jul 2020
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing RPH-104, Olokizumab and Placebo (3 arms). Primary endpoint: Proportion of Responders at Day 15. Started Apr 2020; status: completed.
02
Drugs
olokizumabgoflikicept
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04380519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04380519.